OBR Daily Commentary - ASCO Conference Coverage

forumImage

Incyte Shares Jump After 'IDO' Cancer Immunotherapy Combo Data Revealed

(TheStreet) May 17, 2017 - Attention cancer immunotherapy followers: The ASCO "IDO" party has kicked off. Never-before-seen data from mid-stage clinical trials combining Incyte's IDO inhibitor epacadostat with Keytruda and Opdivo, the anti-PD-1 checkpoint inhibitors marketed by Merck and Bristol-Myers Squibb, respectively, have been released tonight.

H. Jack West, MD (Posted: May 18, 2017)

quotesIn the feeding frenzy that is the business world's hype-driven interpretation of immunotherapy data, the point that the response rate in phase II trials is typically significantly higher than the better established phase III trial data is conveniently overlooked. Could IDO combinations represent a significant improvement? Sure. But docetaxel had a 25% response rate in progressing phase II trials, and carbo/taxol had a 50% response rate as first line treatment in early phase II work, and we all marvel at those crazy numbers when we learn the more sobering reality from far larger clinical trials and greater experience. This kind of breathless over-reaction to early studies is like a Darwin award of investment. Good luck, guys. Just remember that I told you not to jump off the cliff together, like a sea of lemmings. It's the same reflexive rather than conscious thought-driven process.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Much Shorter Chemo Works For Many Colon Cancer Patients, Study Says

(Washington Post/To Your Health) June 4, 2017 - Many colon cancer patients can cut their chemotherapy regimen in half, improving their quality of life and reducing their chances of having debilitating side effects, according to a major international study released Sunday.

Howard S. Hochster, MD (Posted: June 05, 2017)

quotesThe combined analysis of more than 12000 patients in 6 randomize trial was intended to show a noninferiority of 3 months FOLFOX or CapeOX with 95% confidence. As it turned out the HR = 1.07 with 95%CI = 1.0 to 1.15 for the primary endpoint of 3 yr DFS (or 0.9% absolute difference). This means the we have 95% confidence that the shorter course may be equal as much as 1.8% worse at the most. It seems reasonable to assume these are as equal as possible to define. Also, across subsets of good risk (T3 or N1) 3 months was non-inferior. And CapeOX was more effective and non inferior across the board, though this was not a randomized assignment (physician choice in most studies). We can be comfortable that 3 months of CapeOX (and probably FOLFOX) is as good as 6 months treatment for good risk patients receiving adjuvant therapy. quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Quickly Reporting Cancer Complications May Boost Survival

(Associated Press) June 4, 2017 - If you’re being treated for cancer, speak up about any side effects. A study that had patients use home computers to report symptoms like nausea and fatigue surprisingly improved survival — by almost half a year, longer than many new cancer drugs do.

Howard S. Hochster, MD (Posted: June 05, 2017)

quotesIt's not the reporting but early intervention by caregivers to deal with symptoms of chemotherapy treatment. An amazing result! This results in fewer hospitalizations and improved survival. We need to up our game and proactively manage symptoms whether by PRO tools or direct contact. Everyone benefits. quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...